1. Neuroinflammatory disease disrupts the blood-CNS barrier via crosstalk between proinflammatory and endothelial-to-mesenchymal-transition signaling.
- Author
-
Sun Z, Zhao H, Fang D, Davis CT, Shi DS, Lei K, Rich BE, Winter JM, Guo L, Sorensen LK, Pryor RJ, Zhu N, Lu S, Dickey LL, Doty DJ, Tong Z, Thomas KR, Mueller AL, Grossmann AH, Zhang B, Lane TE, Fujinami RS, Odelberg SJ, and Zhu W
- Subjects
- Activin Receptors metabolism, Animals, Central Nervous System metabolism, Mice, Mice, Inbred C57BL, Neuroinflammatory Diseases, Receptor Protein-Tyrosine Kinases metabolism, Signal Transduction, Encephalomyelitis, Autoimmune, Experimental, Monomeric GTP-Binding Proteins metabolism, Multiple Sclerosis
- Abstract
Breakdown of the blood-central nervous system barrier (BCNSB) is a hallmark of many neuroinflammatory disorders, such as multiple sclerosis (MS). Using a mouse model of MS, experimental autoimmune encephalomyelitis (EAE), we show that endothelial-to-mesenchymal transition (EndoMT) occurs in the CNS before the onset of clinical symptoms and plays a major role in the breakdown of BCNSB function. EndoMT can be induced by an IL-1β-stimulated signaling pathway in which activation of the small GTPase ADP ribosylation factor 6 (ARF6) leads to crosstalk with the activin receptor-like kinase (ALK)-SMAD1/5 pathway. Inhibiting the activation of ARF6 both prevents and reverses EndoMT, stabilizes BCNSB function, reduces demyelination, and attenuates symptoms even after the establishment of severe EAE, without immunocompromising the host. Pan-inhibition of ALKs also reduces disease severity in the EAE model. Therefore, multiple components of the IL-1β-ARF6-ALK-SMAD1/5 pathway could be targeted for the treatment of a variety of neuroinflammatory disorders., Competing Interests: Declaration of interests The University of Utah has filed intellectual property concerning ARF6 pathways. The authors declare competing financial interests: The University of Utah has licensed technology to Navigen, a biotechnology company owned in part by the University of Utah Research Foundation. A.L.M. is an employee of Navigen. Correspondence and requests for materials should be addressed to sodelber@genetics.utah.edu or weiquan.zhu@u2m2.utah.edu., (Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF